Odyssey Therapeutics reports positive OD-001 Phase 2a results
Odyssey Therapeutics said OD-001 met Phase 2a success criteria and reported $433 million in cash, expected to fund operations into H2 2028.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.